<code id='828F360586'></code><style id='828F360586'></style>
    • <acronym id='828F360586'></acronym>
      <center id='828F360586'><center id='828F360586'><tfoot id='828F360586'></tfoot></center><abbr id='828F360586'><dir id='828F360586'><tfoot id='828F360586'></tfoot><noframes id='828F360586'>

    • <optgroup id='828F360586'><strike id='828F360586'><sup id='828F360586'></sup></strike><code id='828F360586'></code></optgroup>
        1. <b id='828F360586'><label id='828F360586'><select id='828F360586'><dt id='828F360586'><span id='828F360586'></span></dt></select></label></b><u id='828F360586'></u>
          <i id='828F360586'><strike id='828F360586'><tt id='828F360586'><pre id='828F360586'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:2
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          Biotech incubator Curie.Bio graduates its first startup
          Biotech incubator Curie.Bio graduates its first startup

          ChristophLengauer,co-founderandCSOofCurie.BioVanessaLeroyforSTATCurie.Bio,thenewbiotechinvestmentfir

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          The unintended consequences of overturning Roe v. Wade

          AwomanwaitstogetamedicalabortionataPlannedParenthoodclinicinKansasCity,Kan.CharlieRiedel/APEverydaya